Drug Database
Back to search

Ireland· IE-PA-EU/1/19/1361/001

Skyrizi 75 mg Solution for injection

A interleukin inhibitors product containing risankizumab, registered in Ireland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 3 of our 19 countries.

ATC L04AC

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedSkyrizi 75 mg Solution for injectionATCL04ACREGISTER NO.IE-PA-EU/1/19/1361/001PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about risankizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Risankizumab is registered in 3 of 19 countries.

Countries holding a registration under ATC L04AC (interleukin inhibitors), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 2 of them publish a price we can compare per daily dose
Search risankizumab products by name

Risankizumab · ATC L04AC

3 / 19 countries

  • Belgiumprice
  • Ireland
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
RISANKIZUMAB
Manufacturer
AbbVie Deutschland GmbH & Co. KG
Country
Ireland (IE)
ATC code
L04AC
ATC class
Interleukin inhibitors
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/19/1361/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Risankizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All risankizumab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Skyrizi
  • Iceland · Skyrizi
  • Liechtenstein · Skyrizi
  • Norway · Skyrizi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/030a44ca-2457-414f-91d0-63b59a4fa87a
GET /v1/drugs/030a44ca-2457-414f-91d0-63b59a4fa87a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled syringe",
  "routes": [
    "Subcutaneous use"
  ],
  "source": "hpra",
  "atc_all": [
    "L04AC"
  ],
  "strength": null,
  "pa_number": "EU/1/19/1361/001",
  "substances": [
    "RISANKIZUMAB"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "26/04/2019",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}
API referenceMCP serverPlans

See everything about risankizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console